NIH Confirms Safety Of 2 Experimental Ebola Vaccines

Reuters: Two experimental Ebola vaccines pass safety test in African trial
“Two experimental Ebola vaccines, one from GlaxoSmithKline PLC and the other from biotech start-up NewLink Genetics Corp, ‘appear to be safe’ part way through a clinical trial being conducted in Liberia, the U.S. National Institutes of Health (NIH) said on Thursday…” (Begley, 3/26).

Wall Street Journal: Two Experimental Ebola Vaccines Appear to Be Safe in Trial
“…The safety goals for the vaccines have been met, but proving that they are effective — the next step in the research — now appears to be a more complicated project than originally envisioned. Investigators had planned to enroll 27,000 people in Liberia at a high risk of developing Ebola, such as health care workers…” (Burton, 3/26).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270 | Email Alerts: | |

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.